Filing Flows

Filing Flows › Aktis Oncology (AKTS) › Who owns the stock

Who owns Aktis Oncology (AKTS) stock

104 funds reported Aktis Oncology (AKTS) shares in their latest 13F filings, worth $1.0B in all. The largest holder is MPM BioImpact LLC ($156M). Last quarter 71 funds added to their stakes and 24 cut them.

Largest holders of AKTS (13F)Largest holders of AKTS (13F)MPM BioImpact LLC$156MEcoR1 Capital, LLC$155MBlackRock$73.4MT. Rowe Price Investment Manageme…$66.1MWellington Management Group LLP$63.4MRTW Investments, LP$51.3MRA Capital Management, L.P.$42.4MJupiter Topco LLC$42.4MBaker Bros. Advisors LP$32.1MOctagon Capital Advisors LP$31.0M

Largest holders (13F)

FundSharesValueChangeQuarter
MPM BioImpact LLC4,835,872$156Mnew2026-06-30
EcoR1 Capital, LLC4,824,469$155Mnew2026-06-30
BlackRock2,278,358$73.4Mincrease2026-06-30
T. Rowe Price Investment Management2,051,447$66.1Mdecrease2026-06-30
Wellington Management Group LLP1,966,244$63.4Mdecrease2026-06-30
RTW Investments, LP1,592,043$51.3Munchanged2026-06-30
RA Capital Management, L.P.1,314,405$42.4Mdecrease2026-06-30
Jupiter Topco LLC1,314,267$42.4Mbase2026-06-30
Baker Bros. Advisors LP996,351$32.1Munchanged2026-06-30
Octagon Capital Advisors LP960,847$31.0Munchanged2026-06-30
Merck952,844$30.7Munchanged2026-06-30
Vanguard Capital Management LLC817,075$26.3Mdecrease2026-06-30
Janus Henderson Group1,454,267$26.0Mnew2026-03-31
Price T Rowe Associates763,499$24.6Mdecrease2026-06-30
TCG Crossover Management, LLC696,560$22.5Mnew2026-06-30

Aktis Oncology's latest quarter

Aktis Oncology, Q2 2026: revenue $3.4M (+111% year over year), operating margin -854.0%, net loss $24.1M, operating cash flow −$20.6M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most AKTS stock?

By the latest 13F filings: MPM BioImpact LLC ($156M); EcoR1 Capital, LLC ($155M); BlackRock ($73.4M); T. Rowe Price Investment Management ($66.1M); Wellington Management Group LLP ($63.4M).

What is the short interest in AKTS?

4,313,744 shares were sold short at the 2026-10-15 settlement, -8.52% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.